Simply it goes to show Dimerix has such a low market cap for a company in phase 2b targetting a huge unmet need.
Underpinning this is an actual drug discovery platform which has proven itself through the phase 2a results of DMX200, plus other multiple licencing opportunities such as DMX250.
Not only that but the company is now cashed up well into the future.
If someone can tell me an ASX listed biotech with more potential of being a Disallowed I'd love to hear it!
Simply it goes to show Dimerix has such a low market cap for a...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.015(3.30%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 47.5¢ | 43.0¢ | $1.696M | 3.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69541 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 26902 | 2 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |